Clinicopathological Characteristics of Mucinous Carcinoma of the Breast in Korea: Comparison with Invasive Ductal Carcinoma-Not Otherwise Specified

Park, Seho; Koo, Ja Seung; Kim, Joo Hee; Yang, Woo Ick; Park, Byeong Woo; Lee, Kyong Sik

doi:10.3346/jkms.2010.25.3.361

Cited by 41 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[9] Accordingly, 1.7% of our patients had MBC, consistent with the published data. This disease generally affects the elderly individuals, with <1% of the patients being <35 years of age.…”

Section: Discussionsupporting

confidence: 81%

Mucinous Breast Carcinoma: A Single-Center Experience

Yıldırım¹

2018

TJ Oncol

View full text Add to dashboard Cite

OBJECTIVETo analyze the clinical and histopathological characteristics and treatment outcomes of patients treated and followed up for mucinous breast cancer (MBC). METHODSWe retrospectively analyzed the clinical and histopathological characteristics and treatment outcomes of 22 patients who were diagnosed with and treated for MBC at our center between 2004 and 2016. RESULTSThe mean age was 50 (range: 26-68) years. Ten (47.6%) patients were premenopausal. The tumor was in the right side in 11 patients (50%), and 64% of the patients had early-stage disease. There were six patients with the mixed subtype and 16 with the pure subtype. Except for the two patients with metastatic disease, all patients underwent surgery. Axillary lymph node involvement was detected in seven (36%) patients, and the proportion of patients with the pure subtype was 18%. The average duration of follow-up was 59 months, during which, four patients had recurrent disease. At 5 years, 81% of the patients were alive. The 5-year overall survival rate with pure MBC was 93%. CONCLUSIONMBC is a rare condition and carries a good prognosis. Pure MBC has low axillary lymph node metastasis and a higher survival rate.

show abstract

“…[9] Accordingly, 1.7% of our patients had MBC, consistent with the published data. This disease generally affects the elderly individuals, with <1% of the patients being <35 years of age.…”

Section: Discussionsupporting

confidence: 81%

Mucinous Breast Carcinoma: A Single-Center Experience

Yıldırım¹

2018

TJ Oncol

View full text Add to dashboard Cite

show abstract

“…MC also has a higher rate of oestrogen receptor (ER) expression (73-94% versus 26-82%, supplementary material, Figure S5) and is associated with more progesterone receptor (PR) expression (63-90% versus 47-74%, supplementary material, Figure S6) [137][138][139][140][146][147][148][149][150][151]. For MC, less HER-2 overexpression has been reported compared with NMC (0-14% versus 20-41%, supplementary material, Figure S7) [139,140,146,147,[149][150][151]. Studies that included small numbers of MC demonstrated that mutated PIK3CA, which is found in 16-33% of IDCs, is not a common finding in MC (0-13%), supplementary material, Figure S8 [125,[152][153][154][155][156][157].…”

Section: Mucinous Breast Carcinomamentioning

confidence: 99%

“…MC of the breast is associated with higher rates of MUC2 expression than IDC [98,145]. MC also has a higher rate of oestrogen receptor (ER) expression (73-94% versus 26-82%, supplementary material, Figure S5) and is associated with more progesterone receptor (PR) expression (63-90% versus 47-74%, supplementary material, Figure S6) [137][138][139][140][146][147][148][149][150][151]. For MC, less HER-2 overexpression has been reported compared with NMC (0-14% versus 20-41%, supplementary material, Figure S7) [139,140,146,147,[149][150][151].…”

Section: Mucinous Breast Carcinomamentioning

confidence: 99%

The molecular background of mucinous carcinoma beyond MUC2

Hugen

Simons²,

Halilović³

et al. 2014

Clin J Pathol

View full text Add to dashboard Cite

The increasing interest of the oncology community in tumour classification and prediction of outcome to targeted therapies has put emphasis on an improved identification of tumour types. Colorectal mucinous adenocarcinoma (MC) is a subtype that is characterized by the presence of abundant extracellular mucin that comprises at least 50% of the tumour volume and is found in 10-15% of colorectal cancer patients. MC development is poorly understood, however, the distinct clinical and pathological presentation of MC suggests a deviant development and molecular background. In this review we identify common molecular and genetic alterations in colorectal MC. MC is characterized by a high rate of MUC2 expression. Mutation rates in the therapeutically important RAS/RAF/MAPK and PI3K/AKT pathways are significantly higher in MC compared with non-mucinous adenocarcinoma. Furthermore, mucinous adenocarcinoma shows higher rates of microsatellite instability and is more frequently of the CpG island methylator phenotype. Although the majority of MCs arise from the large intestine, this subtype also develops in other organs, such as the stomach, pancreas, biliary tract, ovary, breast and lung. We compared findings from colorectal MC with tumour characteristics of MCs from other organs. In these organs, MCs show different mutation rates in the RAS/RAF/MAPK and PI3K/ AKT pathways as well, but a common mucinous pathway cannot be identified. Identification of conditions and molecular aberrations that are associated with MC generates insight into the aetiology of this subtype and improves understanding of resistance to therapies.

show abstract

“…The majority of previous MBC clinical studies found that MBC showed higher ER-and PR-positive rates, less lymph node metastasis, lower TNM stage and notably higher OS and DFS rates (16)(17)(18)(19)(20). The present study analyzed the basic information of MBC patients and compared it with that from IDC-NOS patients treated in the same period.…”

Section: Discussionmentioning

confidence: 99%

Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival

et al. 2017

View full text Add to dashboard Cite

Abstract. Mucinous breast carcinoma (MBC) is a rare type of breast cancer, but it has been infrequently studied due to its associated good prognosis. Vascular endothelial growth factor (VEGF) and caspase-3 have been identified to be prognostic factors of infiltrating ductal carcinoma-not otherwise specified (IDC-NOS), but their expression in MBC has not been reported. In the present study, the expression of caspase-3 and VEGF in MBC and IDC-NOS were assessed by immunohistochemistry. Scoring was conducted based on staining intensity and percentage of positive cells. Based on the scores of caspase-3 and VEGF expression, all patient samples were divided into two groups: Low expression (score of 0-5) or high expression (score of 6-12). In total, 42.59% of MBC patients exhibited a high VEGF score compared with 61.67% of the IDC-NOS group (P<0.05). Furthermore, 57.41% of MBC patients exhibited high caspase-3 expression compared with only 33.33% of IDC-NOS patients (P<0.05). VEGF expression in MBC was associated with age, nodal status and tumor-node-metastasis (TNM) stage. Cox univariate analysis showed that higher VEGF expression, positive nodal status and higher TNM stage were associated with shorter disease-free survival (DFS). The Kaplan-Meier method showed that higher VEGF expression in MBC was associated with worse DFS times, while Cox multivariate analysis showed that only TNM stage was significantly associated with DFS. VEGF and caspase-3 expression varied in the MBC and IDC-NOS samples, but neither was directly correlated with DFS in the MBC patients. IntroductionMucinous breast carcinoma (MBC), also known as colloid carcinoma, is a rare subtype of breast tumors that accounts for 1-7% of all breast cancer cases. MBC is characterized by the presence of extracellular mucin (MUC) (1). MBC includes mixed MBC, consisting of other cancer types such as invasive ductal carcinoma, and pure MBC (PMBC), in which the entire mass is almost occupied by mucinous cancer cells and is without conventional invasive ductal carcinoma cells (2). PMBC is represented by a mass with a >90% mucinous component (3). MBC is linked with a more favorable prognosis, a longer disease-free interval and a lower incidence of axillary node metastasis compared with infiltrating ductal carcinoma-not otherwise specified (IDC-NOS) (1,2,4). However, recurrence and metastasis of MBC are frequently present in clinical practice.Angiogenesis is a prerequisite for tumor development; there is a close association between the formation of blood vessels in the vicinity of tumor cells and the potential for tumor formation, invasion and metastasis. Angiogenesis is induced and developed in response to two sets of extracellular signals: soluble angiogenic factors and the extracellular matrix (5). Breast carcinoma has been shown to be an angiogenesisdependent tumor through experimental and clinical data. Vascular endothelial growth factor (VEGF) is the most potent endothelial cell mitogen (6) and a regulator of vascular permeability, therefore, VEGF has been consid...

show abstract

Clinicopathological Characteristics of Mucinous Carcinoma of the Breast in Korea: Comparison with Invasive Ductal Carcinoma-Not Otherwise Specified

Cited by 41 publications

References 27 publications

Mucinous Breast Carcinoma: A Single-Center Experience

Mucinous Breast Carcinoma: A Single-Center Experience

The molecular background of mucinous carcinoma beyond MUC2

Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival

Contact Info

Product

Resources

About